Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Andre M. Bergman"'
Autor:
Aurelia H. M. deVries Schultink, Marie‐Rose B. S. Crombag, Erik vanWerkhoven, Hans‐Martin Otten, Andre M. Bergman, Jan H. M. Schellens, Alwin D. R. Huitema, Jos H. Beijnen
Publikováno v:
Cancer Medicine, Vol 8, Iss 4, Pp 1406-1415 (2019)
Abstract The incidence of neutropenia in metastatic castration‐resistant prostate cancer (mCRPC) patients treated with docetaxel has been reported to be lower compared to patients with other solid tumors treated with a similar dose. It is suggested
Externí odkaz:
https://doaj.org/article/915cd825bb7749d88d3c80c0290c56dc
Autor:
Nikol Snoeren, Richard van Hillegersberg, Sander B. Schouten, Andre M. Bergman, Erikv van Werkhoven, Otilia Dalesio, Rob A.E.M. Tollenaar, Henk M. Verheul, Joost van der Sijp, Inne H.M. Borel Rinkes, E.E. Voest
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 2, Pp 93-99 (2017)
Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). Recurrence after resection of colorectal liver metastases (CRLMs), presumably caused by VEGF-mediated outgrowth of micrometastases, might decrease whe
Externí odkaz:
https://doaj.org/article/8540aee29ed24edfb5097530285c804e
Autor:
Daniel P. Petrylak, Raffaele Ratta, Nobuaki Matsubara, Ernesto Pablo Korbenfeld, Rustem Gafanov, Loic Mourey, Tilman Todenhöfer, Howard Gurney, Gero Kramer, Andre M. Bergman, Pawel Zalewski, Maria De Santis, Andrew J. Armstrong, Winald R. Gerritsen, Russell Kent Pachynski, Todd L. Saretsky, Sameer R. Ghate, Xin Tong Li, Charles Schloss, Karim Fizazi
Publikováno v:
Journal of Clinical Oncology. 41:129-129
129 Background: The double-blind, phase 3, randomized KEYNOTE-921 trial (NCT03834506) showed that pembro + docetaxel did not significantly improve rPFS or OS for pts with mCRPC treated with prior next-generation hormonal agent (NHA) therapy. We prese
Autor:
Ronan Flippot, Tugce Telli, Maud Velev, Aude Flechon, Lea Turpin, Andre M. Bergman, Fabio Turco, Wolfgang Peter Fendler, Anne Laure Giraudet, Françoise Montravers, Wouter V. Vogel, Silke Gillessen, Simona Berardi, Ken Herrmann, David Kryza, Gaetano Paone, Camilo Garcia, Stéphanie Foulon, Arnaud Pages, Karim Fizazi
Publikováno v:
Journal of Clinical Oncology. 41:180-180
180 Background: Cabazitaxel and Lu-PSMA both improved survival in patients with mCRPC after docetaxel and an androgen receptor pathway inhibitor (ARPI), but there is limited data regarding Lu-PSMA activity after cabazitaxel. We aimed at assessing act
Autor:
Daniel P. Petrylak, Raffaele Ratta, Nobuaki Matsubara, Ernesto Pablo Korbenfeld, Rustem Gafanov, Loic Mourey, Tilman Todenhöfer, Howard Gurney, Gero Kramer, Andre M. Bergman, Pawel Zalewski, Maria De Santis, Andrew J. Armstrong, Winald R. Gerritsen, Russell Kent Pachynski, Seok-Soo Byun, Xin Tong Li, Charles Schloss, Christian Heinrich Poehlein, Karim Fizazi
Publikováno v:
Journal of Clinical Oncology. 41:19-19
19 Background: Docetaxel is a treatment option following disease progression on a next-generation hormonal agent (NHA) for patients with mCRPC, but there is an urgent need for more efficacious treatments. The randomized, double-blind, phase 3 KEYNOTE
Autor:
Renske M.T. ten Ham, Alwin D. R. Huitema, Rick A. Vreman, Andre M. Bergman, Hilde Rosing, Merel van Nuland, Anke M. Hövels, Laurens G. de Graaf, Jos H. Beijnen
Publikováno v:
Value in Health. 24:121-128
Objectives Abiraterone acetate is registered for the treatment of metastatic castration-sensitive and resistant prostate cancer (mCRPC). Treatment outcome is associated with plasma trough concentrations (Cmin) of abiraterone. Patients with a plasma C
Autor:
Winald R. Gerritsen, A.C.M. van den Bergh, Inge M. van Oort, Ronald de Wit, Carin A. Uyl-de Groot, Andre M. Bergman, Malou C.P. Kuppen, Reindert J.A. van Moorselaar, Hans M. Westgeest, Jules Lavalaye, Metin Tascilar, Alfons J.M. van den Eertwegh, Diederik M. Somford, Niven Mehra, Katja K.H. Aben
Publikováno v:
Clinical genitourinary cancer, 20(1), 43-52. CIG MEDIA GROUP, LP
Clinical Genitourinary Cancer, 20(1), 43-52. Elsevier
Clinical Genitourinary Cancer, 20, 43-52
Clinical Genitourinary Cancer, 20, 1, pp. 43-52
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Tascilar, M, Mehra, N, Lavalaye, J, Somford, D M, Aben, K K H, Bergman, A M, de Wit, R, van den Bergh, A C M, de Groot, C A U & Gerritsen, W R 2022, ' Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population : Results From the CAPRI-Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 20, no. 1, pp. 43-52 . https://doi.org/10.1016/j.clgc.2021.10.008
Clinical Genitourinary Cancer, 20(1), 43-52. Elsevier
Clinical Genitourinary Cancer, 20, 43-52
Clinical Genitourinary Cancer, 20, 1, pp. 43-52
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Tascilar, M, Mehra, N, Lavalaye, J, Somford, D M, Aben, K K H, Bergman, A M, de Wit, R, van den Bergh, A C M, de Groot, C A U & Gerritsen, W R 2022, ' Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population : Results From the CAPRI-Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 20, no. 1, pp. 43-52 . https://doi.org/10.1016/j.clgc.2021.10.008
Contains fulltext : 248303.pdf (Publisher’s version ) (Open Access) BACKGROUND: Patients with metastatic castration resistant prostate cancer (mCRPC) are at risk of symptomatic skeletal events (SSE). Bone health agents (BHA, ie bisphosphonates and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27d177b59c6e2b3659b939a21de276f6
https://research.rug.nl/en/publications/6aff08ca-2583-4fbf-80f0-7e6b97065874
https://research.rug.nl/en/publications/6aff08ca-2583-4fbf-80f0-7e6b97065874
Autor:
N.I. Weijl, Carin A. Uyl-de Groot, Lidwine W. Tick, Andre M. Bergman, Winald R. Gerritsen, Daan ten Bokkel Huinink, Hans M. Westgeest, Jules Lavalaye, Katja K.H. Aben, Inge M. van Oort, Fons A.J.M. van den Eertwegh, Malou C.P. Kuppen, Menuhin I. Lampe, Yes A J van de Wouw, Jeroen R.J.A. van Moorselaar, Joan van den Bosch, Juleon L.L.M. Coenen, Rik D.M. Somford, Tineke J. Smilde, Niven Mehra, Mathijs P. Hendriks
Publikováno v:
Westgeest, H M, Kuppen, M C P, van den Eertwegh, F A J M, van Oort, I M, Coenen, J L L M, van Moorselaar, J R J A, Aben, K K H, Bergman, A M, Huinink, D T B, van den Bosch, J, Hendriks, M P, Lampe, M I, Lavalaye, J, Mehra, N, Smilde, T J, Somford, R D M, Tick, L, Weijl, N I, van de Wouw, Y A J, Gerritsen, W R & Groot, C A U 2021, ' High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients : Results from the Dutch CAPRI-Registry ', Journal of Palliative Medicine, vol. 24, no. 12, pp. 1789-1797 . https://doi.org/10.1089/jpm.2020.0800
Journal of Palliative Medicine, 24(12), 1789-1797. Mary Ann Liebert Inc.
Journal of Palliative Medicine, 24, 12, pp. 1789-1797
Journal of Palliative Medicine, 24, 1789-1797
Journal of Palliative Medicine, 24(12), 1789-1797. Mary Ann Liebert Inc.
Journal of Palliative Medicine, 24, 12, pp. 1789-1797
Journal of Palliative Medicine, 24, 1789-1797
Background: Intensive end-of-life care (i.e., the overuse of treatments and hospital resources in the last months of life), is undesirable since it has a minimal clinical benefit with a substantial financial burden. The aim was to investigate the car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df4add06b482c8b42c6f4158cc5bdf89
https://research.vumc.nl/en/publications/13bcb35e-f6d1-4c15-a1e8-8d67db323f51
https://research.vumc.nl/en/publications/13bcb35e-f6d1-4c15-a1e8-8d67db323f51
Autor:
Diederik M. Somford, Reindert J.A. van Moorselaar, Carin A. Uyl-de Groot, Ronald de Wit, Laurent M.C.L. Fossion, Niven Mehra, Hans M. Westgeest, Addy C. M. van de Luijtgaarden, Juleon L.L.M. Coenen, N.I. Weijl, Maud M. Geenen, Winald R. Gerritsen, Agnes J. van de Wouw, A.C.M. van den Bergh, Mathijs P. Hendriks, Marco B. Polee, Alphonsus J. M. van den Eertwegh, Andre M. Bergman, Malou C.P. Kuppen, Inge M. van Oort, Daan ten Bokkel Huinink
Publikováno v:
European urology oncology, 4(4), 618-627. De Tijdstroom/Elsevier
European Urology Oncology, 4, 618-627
European urology oncology, 4, 618-627. Elsevier
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Coenen, J L L M, van den Bergh, A C M F, Mehra, N, Somford, D M, Bergman, A M, Ten Bokkel Huinink, D, Fossion, L, Geenen, M M, Hendriks, M P, van de Luijtgaarden, A C M, Polee, M B, Weijl, N I, van de Wouw, A J, de Wit, R, Uyl-de Groot, C A & Gerritsen, W R 2021, ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer : Results from the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Oncology, vol. 4, no. 4, pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005
European Urology Oncology, 4, 4, pp. 618-627
European Urology Oncology, 4(4), 618-627. Elsevier BV
European Urology Oncology, 4, 618-627
European urology oncology, 4, 618-627. Elsevier
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Coenen, J L L M, van den Bergh, A C M F, Mehra, N, Somford, D M, Bergman, A M, Ten Bokkel Huinink, D, Fossion, L, Geenen, M M, Hendriks, M P, van de Luijtgaarden, A C M, Polee, M B, Weijl, N I, van de Wouw, A J, de Wit, R, Uyl-de Groot, C A & Gerritsen, W R 2021, ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer : Results from the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Oncology, vol. 4, no. 4, pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005
European Urology Oncology, 4, 4, pp. 618-627
European Urology Oncology, 4(4), 618-627. Elsevier BV
Background: Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI + P] or enzalutamide [ENZ]) for treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect responses to s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5688ade1d20f2f2f131d73a057ff810
https://research.rug.nl/en/publications/41b16b5e-d8f6-46e7-904f-77d48f068028
https://research.rug.nl/en/publications/41b16b5e-d8f6-46e7-904f-77d48f068028
Autor:
Haiko J. Bloemendal, Niven Mehra, Marco B. Polee, Joan van den Bosch, Alphonsus J. M. van den Eertwegh, Carin A. Uyl-de Groot, Daan ten Bokkel Huinink, H. P. (Pieter) van den Berg, Andre M. Bergman, Inge M. van Oort, Malou C.P. Kuppen, Addy C. M. van de Luijtgaarden, Laurent M.C.L. Fossion, Mathijs P. Hendriks, Juleon L.L.M. Coenen, Winald R. Gerritsen, Hans M. Westgeest, A.C.M. van den Bergh, Ronald de Wit, N.I. Weijl
Publikováno v:
Clinical Genitourinary Cancer, 17, 5, pp. e946-e956
Clinical Genitourinary Cancer, 17(5), E946-E956. Elsevier
Clinical genitourinary cancer, 17(5), E946-E956. CIG MEDIA GROUP, LP
Westgeest, H M, Kuppen, M C P, van den Eertwegh, A J M, de Wit, R, Coenen, J L L M, van den Berg, H P, Mehra, N, van Oort, I M, Fossion, L M C L, Hendriks, M P, Bloemendal, H J, van de Luijtgaarden, A C M, ten Bokkel Huinink, D, van den Bergh, A C M, van den Bosch, J, Polee, M B, Weijl, N, Bergman, A M, Uyl-de Groot, C A & Gerritsen, W R 2019, ' Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 17, no. 5, pp. e946-e956 . https://doi.org/10.1016/j.clgc.2019.05.018
Clinical Genitourinary Cancer, 17(5), e946-e956. Elsevier
Clinical Genitourinary Cancer, 17, e946-e956
Clinical Genitourinary Cancer, 17(5), E946-E956. Elsevier
Clinical genitourinary cancer, 17(5), E946-E956. CIG MEDIA GROUP, LP
Westgeest, H M, Kuppen, M C P, van den Eertwegh, A J M, de Wit, R, Coenen, J L L M, van den Berg, H P, Mehra, N, van Oort, I M, Fossion, L M C L, Hendriks, M P, Bloemendal, H J, van de Luijtgaarden, A C M, ten Bokkel Huinink, D, van den Bergh, A C M, van den Bosch, J, Polee, M B, Weijl, N, Bergman, A M, Uyl-de Groot, C A & Gerritsen, W R 2019, ' Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 17, no. 5, pp. e946-e956 . https://doi.org/10.1016/j.clgc.2019.05.018
Clinical Genitourinary Cancer, 17(5), e946-e956. Elsevier
Clinical Genitourinary Cancer, 17, e946-e956
In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily p